News

Press Releases

Patent Application Covering a Novel Production Method for Ingenol Mebutate at Phyton Biotech is Published by World Intellectual Property Organization (WIPO)

Ahrensburg, Germany and Fort Worth, TX — (PR Newswire) — 09/29/16 – Phyton Biotech, the pioneer in Plant Cell Fermentation (PCF®), today announced that its international patent application PCT/EP2016/055989 “PRODUCTION OF INGENOL, INGENOL ESTERS AND/OR TIGLIAN-3-ONE DERIVATIVES BY EUPHORBIACEAE PLANT CELL CULTURE,” has been published by the World Intellectual Property Organization (WIPO).  “Read More

 

 

Phyton Biotech AchievesManufacturing Milestone with Thapsigargin, the Active Agent in Mipsagargin

AHRENSBURG, Germany – (August 22, 2016) – Phyton Biotech today announced that it has
achieved a major milestone in connection with the manufacture of thapsigargin, an inhibitor derived from the Thapsia plant that is the active agent for the investigational prodrug mipsagargin.  “Read More

Active Substances from Plants: Bioreactor Modules Share Production Work. Scientists of KIT and Phyton Biotech GmbH Technically Reproduce Complex Plant Tissue for More Effective Production of Active Substances against Cancer and Alzheimer’s Disease. 

KARLSRUHE, GERMANY – 03/13/2016 – Plants produce a number of substances that can be used to treat cancer, Alzheimer’s or Parkinson’s disease. Frequently, however, metabolic pathways to obtain the target substance are so complex that its biotechnological production is hardly effective and very expensive. Scientists of KIT now combine their expertise with the technical know-how of Phyton Biotech GmbH, the biggest producer of pharmaceutical ingredients with plant cells. Read More

Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO).  Production of Thapsigargins by Thapsia Cell Suspension Culture” Filed by Phyton Biotech.

SAN ANTONIO, TEXAS — (Marketwired) — 07/13/2015 — GenSpera, Inc. (OTCQB: GNSZ) today announced that its strategic partner Phyton Biotech, the pioneer in Plant Cell Fermentation  (PCF®), has had its international patent application WO 2015/0892978 A1 “PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE,” published by the World Intellectual Property Organization (WIPO). Read More

GenSpera Announces Partnership With Global Supplier

SAN ANTONIO, TEXAS – 02/09/2015 –  GenSpera, Inc. (OTCQB: GNSZ) today announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company’s investigational agent mipsagargin. Phyton Biotech will offer its Plant Cell Fermentation (PCF®) development expertise to convert the thapsia plant into a preserved, fermentable cell line with a goal of creating a sustainable source of high quality thapsigargin. Read More

Phyton Biotech Launches New Website

VANCOUVER, CANADA – 10/01/2014 – Phyton Biotech, the pioneer in plant cell fermentation (PCF®) technology with the world’s largest capacity for paclitaxel and docetaxel API via PCF,  has launched a new website: www.phytonbiotech.com. The new website maintains Phyton’s commitment to being the best commercial supplier of paclitaxel and docetaxel API in the world and also emphasizes Phyton’s increased focus on Development Services for plant-derived actives via PCF and for complex small molecules. Read More

Phyton Biotech Receives CEP for Paclitaxel API Produced by Plant Cell Fermentation

VANCOUVER, CANADA – 07/17/2012 – Phyton Biotech, a global supplier of high quality paclitaxel and docetaxel API, has been granted a Certificate of suitability to European Pharmacopeia (CEP) bythe European Directorate for the Quality of Medicines and HealthCare (EDQM) for its paclitaxel activepharmaceutical ingredient (API) produced from plant cell fermentation. Phyton’s CEP application was filed in October, 2011. Read More

Phyton Biotech Receives CEP for Docetaxel API

VANCOUVER, CANADA – 06/10/2013 – Phyton Biotech, a global supplier of high quality paclitaxel and docetaxel API, has been granted a Certificate of suitability to European Pharmacopeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its docetaxel anhydrous active pharmaceutical ingredient (API). Phyton is the first North American or European based contract API supplier to be granted a CEP for docetaxel. Importantly, Phyton’s docetaxel API is not subject to the current worldwide shortage of 10-deacetylbaccatin (10-DAB) starting material because it uses paclitaxel from its own plant cell fermentation facility as its starting material. Read More

Phyton Biotech Receives “Research Group of the Year” Award

HAMBURG, GERMANY – 10/17/2011 – Phyton Biotech announced that it has won the international “Research Group of the Year” 2011 Life Science Award from Select Biosciences. The award was presented on June 29th at the inaugural European Lab automation congress in Hamburg, Germany. An international panel of judges, all experts in Life Sciences, selected Phyton Biotech from a group of three finalists. Read More

Phyton Biotech Acquires Assets of Natural Pharmaceuticals, Inc.

SAN ANTONIO, TEXAS – 10/12/2009 – Phyton Biotech, LLC (Phyton), an affiliate of Phyton, Inc., today announced that it has purchased the assets of Natural Pharmaceuticals, Inc. (NPI), a leading manufacturer of oncology drug active pharmaceutical ingredients (APIs). Read More